Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma Meeting Abstract

  

Authors:	Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; Rueda, C.; Lahoud, O.; Shah, G.; Scordo, M.; Chung, D.; Landau, H.; Giralt, S.; Usmani, S.; Lesokhin, A.; Korde, N.
Abstract Title:	Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
Meeting Title:	20th Annual Meeting and Exposition of the International Myeloma Society
Journal Title:	Clinical Lymphoma, Myeloma and Leukemia
Volume:	23
Issue:	Suppl. 2
Meeting Dates:	2023 Sep 27-30
Meeting Location:	Athens, Greece
ISSN:	2152-2650
Publisher:	Elsevier Inc.
Date Published:	2023-09-01
Start Page:	S127
Language:	English
ACCESSION:	WOS:001079705400218
PROVIDER:	Clarivate Analytics Web of Science
PROVIDER:	wos
DOI:	10.1016/S2152-2650(23)01784-6
Notes:	Meeting Abstract: P-166 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/211909